Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL61153 | 0.84 | LMNA (0.33) | LMNATRPA1PTGS1CACNA1C | |
| SCHEMBL28469091 | 0.81 | LMNA (0.32) | LMNATRPA1PTGS1CACNA1C | |
| SCHEMBL1069616 | 0.78 | — | — | |
| SCHEMBL11789282 | 0.78 | USP2 (0.35) | — | |
| SCHEMBL16960056 | 0.75 | GABRA1 (0.34) | — | |
| SCHEMBL3292706 | 0.75 | GABRA1 (0.30) | — | |
| SCHEMBL27534 | 0.74 | — | — | |
| SCHEMBL16957307 | 0.73 | GABRA1 (0.35) | TRPA1PTGS1CACNA1C | |
| SCHEMBL16952824 | 0.73 | GABRA1 (0.33) | — | |
| SCHEMBL16956033 | 0.73 | GABRA1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 195 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4327881-A2 | PROCESSES FOR THE PREPARATION OF GLASDEGIB AND SALT THEREOF AND SOLID STATE FORMS OF GLASDEGIB MALEATE AND PROCESS FOR PREPARATION THEREOF | Assia Chemical Industries LTD (IL) | 2024-02-28 | — | — | EP | claimed |
| US-20230107634-A1 | PROCESSES FOR THE PREPARATION OF GLASDEGIB AND SALT THEREOF AND SOLID STATE FORMS OF GLASDEGIB MALEATE AND PROCESS FOR PREPARATION THEREOF | TEVA PHARMACEUTICALS INT GMBH (CH) | 2023-04-06 | — | — | US | claimed |
| EP-4097093-A1 | PROCESSES FOR THE PREPARATION OF GLASDEGIB AND SALT THEREOF AND SOLID STATE FORMS OF GLASDEGIB MALEATE AND PROCESS FOR PREPARATION THEREOF | Teva Pharmaceuticals International GmbH (CH) | 2022-12-07 | — | — | EP | claimed |
| EP-3523292-B1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2021-12-15 | — | — | EP | claimed |
| US-20210371398-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2021-12-02 | — | — | US | claimed |
| WO-2021154901-A1 | PROCESSES FOR THE PREPARATION OF GLASDEGIB AND SALT THEREOF AND SOLID STATE FORMS OF GLASDEGIB MALEATE AND PROCESS FOR PREPARATION THEREOF | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2021-08-05 | — | — | WO | claimed |
| US-10913730-B2 | Heteroaryl compounds and their use as Mer inhibitors | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2021-02-09 | — | — | US | claimed |
| US-20190315716-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | DONG-A ST CO., LTD. (KR) | 2019-10-17 | — | — | US | claimed |
| EP-3523292-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | Dong-A Socio Holdings Co., Ltd. (KR) | 2019-08-14 | — | — | EP | claimed |
| CN-105980365-B | Benzimidazol-2-amines as mIDH1 inhibitors | 拜耳医药股份公司 | 2019-06-21 | — | — | CN | claimed |
| WO-2004009533-A1 | ACETYLAMINO BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS, INC. (US) | 2004-01-29 | — | — | WO | claimed |
| US-20030013718-A1 | Phthalazine derivatives for treating inflammatory diseases | NOVARTIS AG (CH) | 2003-01-16 | — | — | US | claimed |
| CN-1367695-A | Phthalazine derivatives for the treatment of inflammatory diseases | NOVARTIS AG (CH) | 2002-09-04 | — | — | CN | claimed |
| EP-1194417-A1 | PHENOXY FLUOROPYRIMIDINES | BAYER AG (DE) | 2002-04-10 | — | — | EP | claimed |
| EP-1165085-A1 | PHTHALAZINE DERIVATIVES FOR TREATING INFLAMMATORY DISEASES | Novartis AG (CH) | 2002-01-02 | — | — | EP | claimed |
| WO-2000078733-A1 | PHENOXY FLUOROPYRIMIDINES | BAYER AKTIENGESELLSCHAFT (DE) | 2000-12-28 | — | — | WO | claimed |
| WO-2000059509-A1 | PHTHALAZINE DERIVATIVES FOR TREATING INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2000-10-12 | — | — | WO | claimed |
| US-4272441-A | CARBAMYLATION, PHOSGENE, ALCOHOL, AMINE | FMC CORPORATION (US) | 1981-06-09 | — | — | US | claimed |
| US-3941829-A | PESTICIDE | CIBA-GEIGY CORPORATION (US) | 1976-03-02 | — | — | US | claimed |
| US-3935250-A | PESTICIDE | CIBA-GEIGY CORPORATION (US) | 1976-01-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913730-B2 | Heteroaryl compounds and their use as Mer inhibitors | MERTK, RET, ERBB4 | LMNA 1281/4885TRPA1 3486/4885PTGS1 4138/4885 |
| US-20030013718-A1 | Phthalazine derivatives for treating inflammatory diseases | FLT1, KDR, FFAR2 | LMNA 2857/4885TRPA1 1717/4885PTGS1 76/4885 |
| US-20190315716-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | MERTK, RET, ERBB4 | LMNA 1281/4885TRPA1 3486/4885PTGS1 4138/4885 |
| US-20230107634-A1 | PROCESSES FOR THE PREPARATION OF GLASDEGIB AND SALT THEREOF AND SOLID STATE FORMS OF GLASDEGIB MALEATE AND PROCESS FOR PREPARATION THEREOF | GLS, SLC16A3, SLC5A2 | LMNA 2919/4885TRPA1 3482/4885PTGS1 1528/4885 |
| US-20210371398-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | MERTK, RET, ERBB2 | LMNA 1144/4885TRPA1 3111/4885PTGS1 3804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.